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Summary. Background: Prevention of arthropathy is a major
goal of hemophilia treatment. While studies in adults have
demonstrated an impact of prophylaxis on the incidence of joint
bleeds and patients well-being in terms of improved quality of
life (QoL), it is unclearwhetherornotprophylaxis inﬂuences the
outcome and perception of well- of children with hemophilia.
Objective: This randomized controlled study compared the
eﬃcacy of prophylaxis with episodic therapy in preventing
hemarthroses and image-proven joint damage in children with
severe hemophilia A (factor VIII <1%) over a 10-year time
period.Methods: Forty-ﬁve children with severe hemophilia A,
aged 1–7 years (median 4), with negative clinical-radiologic
joint score at entry and at least one bleed during the previous
6 months, were consecutively randomized to prophylaxis
with recombinant factorVIII (25 IU kg)1 3 ·week) or episodic
therapy with ‡25 IU kg)1 every 12–24 h until complete clinical
bleeding resolution. Safety, feasibility, direct costs and QoL
were also evaluated.Results:Twenty-one childrenwere assigned
to prophylaxis, 19 to episodic treatment. Children on prophy-
laxis had fewer hemarthroses than children on episodic therapy:
0.20 vs. 0.52 events per patient per month (P < 0.02). Plain-
ﬁlm radiology showed signs of arthropathy in six patients on
prophylaxis (29%) vs. 14 on episodic treatment (74%) (P <
0.05). Prophylaxis was more eﬀective when started early (£36
months), with patients having fewer joint bleeds (0.12 joint
bleeds per patient permonth) and no radiologic signs of arthro-
pathy. Conclusion: This randomized trial conﬁrms the eﬃcacy
of prophylaxis in preventing bleeds and arthropathy in children
with hemophilia, particularly when it is initiated early in life.
Keywords: episodic treatment, Haemo-QoL, hemarthrosis,
hemophilia A, prophylaxis, quality of life.
Introduction
The most common hemorrhagic manifestations of hemophilia
are recurrent hemarthroses, mainly in elbows, knees and
ankles, which lead to a progressive joint destruction, irrevers-
ible crippling arthropathy and chronic pain [1]. Hence,
prevention of arthropathy is the main goal of hemophilia
therapy by means of the replacement of the deﬁcient coagu-
lation factor with concentrates, which can be administered
episodically or regularly. Episodic therapy (i.e. the administra-
tion of concentrates on the occasion of bleeding) has been
shown to decrease mortality and to slow the progression to
arthropathy, but not to prevent it [2]. The long-term, regular,
continuous administration of concentrates, based upon two to
three or more weekly infusions, is the most effective method to
forestall bleeding and bleeding-related complications [3], and
therefore it was described as prophylaxis. A very early
prophylaxis started before or at the time of the ﬁrst bleed
and within the second year of age, when joints are presumably
still pristine, is called primary prophylaxis [4,5]. Prophylaxis
started later is called secondary prophylaxis, because even after
only a few bleeding episodes in the same joint, irreversible
articular changes may have already occurred [3,6].
There are barriers to early and long-term prophylaxis in
children with hemophilia, mainly related to cumbersome
venous access leading to inadequate patient/family compliance
with the prescribed treatment. There are also important issues
related to the need for considerable human and economic
resources. The superiority of prophylaxis compared with
episodic replacement therapy, apart from an obvious biologic
rationale, had been based until recently on weak evidence [7].
The great majority of the studies were retrospective [3,6] and
the strongest but indirect evidence was provided by a longitu-
dinal, uncontrolled, international cohort study carried out
between 1986 and 1992 [8]. This study showed that a better
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orthopedic outcome was associated with a lower frequency of
joint bleeds, and that continuous prophylaxis produced the best
orthopedic outcome.Much stronger evidence on the efﬁcacy of
prophylaxis was provided in 2007 by the ﬁrst prospective
randomized study comparing prophylaxis and episodic therapy
[9].
There are still several unresolved issues concerning prophy-
laxis in childhood: the efﬁcacy in preventing arthropathy,
particularly when prophylaxis is not started in the very ﬁrst
years of life; its feasibility in terms of compliance; venous access
and complications related to indwelling catheters; the dosing
regimen; cost-effectiveness; and effects on patients quality of
life (QoL) [10,11]. In order to answer these questions, we
designed in 1996 a randomized controlled pragmatic trial,
named ESPRIT (an acrostic from Evaluation Study on
Prophylaxis: a Randomized Italian Trial), with the goal of
comparing the efﬁcacy of prophylaxis with episodic therapy in
preventing joint bleeds and arthropathy in children with severe
hemophilia A (factor VIII, <1%) over a time period of
10 years, to help inform the choice between options for care
[12]. The decision to employ a randomized controlled trial
design was justiﬁed at that time by the fact that in the 1990s the
standard care for patients in Italy, but also in the majority of
other countries, was episodic therapy.
Patients and methods
Study design
We designed an independent, multicentre, parallel group,
randomized, comparative, open, pragmatic trial, in order to
evaluate whether or not prophylaxis was more effective than
episodic therapy in preventing joint bleeding and joint damage
in young children with severe hemophilia A. We chose an open
study design because patient blinding was deemed unfeasible
for ethical and practical reasons.
Study objectives
The hypotheses of the study were that prophylactic treatment
of children with severe hemophilia A would (i) reduce the rate
of bleeding and (ii) reduce the rate of joint damage. The study
was designed to capture long-term effects of prophylaxis by
means of a long follow-up. In addition, the study had the goal
of comparing safety, feasibility, direct costs of health care, cost-
effectiveness and quality of life.
Eligibility criteria
All severe hemophilia A patients (FVIII activity level <1%),
without measurable inhibitors (<0.6 BU mL)1), with an age
ranging from 1 to 7 years, were candidates for inclusion in the
study. Exclusion criteria were: any clinical or radiologic signs of
joint damage, in order to exclude patients with already
established arthropathy; no bleeding episodes in the previous
6 months, in order to exclude patients with mild bleeding
frequency; a history of more than two bleeding episodes in the
same joint or muscle, in order to exclude patients with already
damaged joints not detected by clinical examination or
imaging; concomitant severe chronic diseases or congenital
skeletal malformations; and unreliability or likelihood of poor
compliance with the long-term follow-up.
Recruitment sites
Eligible patients were consecutively recruited in 12 hemophilia
comprehensive care centres of the 36 existing in Italy in 1996;
these centres were uniformly distributed all over the country (a
list of the centres is provided in Appendix 1). The study
protocol and patient information sheet were approved by the
Institutional Review Board of each participating centre.
Parents or legal guardians of eligible patients gave written
informed consent.
Randomization and treatments
Patients were randomly assigned following a centralised, simple
randomisation procedure (computerised random numbers), to
be treated on prophylaxis with a ﬁrst generation recombinant
FVIII concentrate (rFVIII; Recombinate, Baxter, Deerﬁeld,
IL, USA) at the dose of 25 IU kg)1 three times a week on non-
consecutive days, or episodically (i.e. at the time of occurrence
of a bleeding event) with the same product at a dosage of
25 IU kg)1 or more, possibly within 6 h from the event, this
treatment being repeated every 12–24 h until complete resolu-
tion of the bleeding episode. Breakthrough bleeds occurring in
patients enrolled in the prophylaxis arm had to be treated with
extra doses of concentrate in the same way. Dosages used in
prophylaxis could be adjusted according to the supervisors
judgement, depending on any one of the following variables:
occurrence of frequent breakthrough bleeding, vial size
(500 IU/vial) and maintenance of FVIII trough levels above
1%. In 2004, Recombinate was no longer commercially
available in Italy, so all patients were switched to a third
generation rFVIII (Advate, Baxter, USA).
Treatments were administered by one of the family members
at home, as this was common practise in these patients in Italy.
The protocol allowed early change of the assigned treatment
when it was deemed inadequate by the supervisor, owing to one
of the following reasons: a high frequency of bleeding episodes
(deﬁned as 3 monthly bleeds or more), development of a target
joint (deﬁned as three bleeds in the same joint in a 6-month time
period), life-threatening hemorrhage; or bone or cartilage
damage on joint imaging. Patients continued to be followed-up
and were analysed on intention-to-treat basis. Patients were
removed at the time of development of inhibitors or withdrawal
of participation consent or when lost to follow-up.
Outcomes
The primary endpoint pertaining to efﬁcacy was the overall
frequency of clinically signiﬁcant bleeding events (deﬁned as
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bleeding events requiring replacement therapy) and the occur-
rence and severity of joint damage (as ascertained by plain ﬁlm
radiography of elbows, knees and ankles). Frequency of
bleeding was chosen as the primary outcome because it is
correlated with a worse orthopedic outcome [8], so it is a
reliable short-term surrogate marker of efﬁcacy. The caregivers
were asked to ﬁll in a patient diary reporting date, time and site
of bleeding, which required treatment, date and time of
concentrate infusion and units infused. Patients diaries were
then reviewed with the caregivers every 3 months.
In addition, a second primary outcome was included (i.e. the
radiologic changes of the most frequently involved joints).
Radiologic evaluation, scheduled at study entry, every
2.5 years and at the end of the follow-up period, was carried
out according to the Pettersson radiologic score [13], which
takesmainly into account joint structural changes. Radiograms
were evaluated by an independent radiologist (BL), unaware of
the treatment arm. The studywas planned to last 10 years from
the time of enrollment of the ﬁrst patient.
Secondary analyses were carried out on the frequency of
hemarthroses, presence of clinical signs of musculoskeletal
involvement, compliance, inhibitor development, need for the
use of central venous catheters and related complications,
trough FVIII levels (in the prophylaxis arm), overall amount
of concentrates used, direct costs and health-related quality of
life (HRQoL). The orthopedic assessment of elbows, knees
and ankles was carried out every year, according to the World
Federation of Hemophilia Orthopaedic Joint Score [14],
which takes into account range of motion, presence of
muscular atrophy, presence of chronic synovitis or deformity.
This evaluation was performed by a trained clinician in each
centre, who was unaware of the treatment group. Feasibility
of treatment and patient compliance were evaluated through-
out the trial period in terms of number of bleeding episodes
not properly treated (delayed or missed treatment), number of
missed infusions, efﬁciency and adequacy of any needed
subcutaneous venous port and patient and family acceptance
of the assigned treatment. Compliance with study medication
was assessed by requesting patients parents to record all
infusions and bleeding episodes and their treatment in a
special diary and checking it at each visit at the hemophilia
centre. In cases of apparently poor compliance, instructions
were reinforced and checked at appropriate intervals. In
patients randomized to prophylaxis, plasma levels of FVIII
coagulant activity were obtained every 6 months immediately
prior to one of the regularly scheduled infusions, in order to
determine if trough levels were above 1%. In the case of
FVIII levels being lower than or equal to 1%, the dose
regimen had to be adjusted by increasing the dose of the
infusion before the longest interval or of each infusion up to
40 IU kg)1. These evaluations were performed on the most
critical day (for example, on Monday, when the schedule was
Monday, Wednesday, Friday). Plasma for FVIII recovery
(30 min post-infusion) and inhibitor levels were carried out
every month for the ﬁrst 6 months, every 3 months for the
following 18 months, every year thereafter and whenever the
treating physician felt that there was a poor clinical response
to FVIII infusion.
Cost evaluation was mainly based on the annual FVIII
consumption, which accounts for up to 95%of the overall costs
[15,16].Althoughthegeneralperspectiveadoptedinthisstudyisa
societalone,healthcareresourcesabsorbedbythecareofpatients
were speciﬁcally considered. Hence, resources absorbed have
beenquantiﬁed intomonetary terms adopting theperspective of
the third party payer (i.e. the Italian National Health Service
(NHS)). All costs are expressed in Euros as at 2010.
The psychological impact in patients and their families was
compared in the two treatment arms only at the end of the
follow-up period by means of a disease-speciﬁc QoL question-
naire (Haemo-QoL) [17]. The Haemo-QoL questionnaire is
available as a self-report instrument for children of three
different age groups (I, 4-7; II, 8-12; III, 13–16 years) and as
corresponding proxy versions for parents. Item responses of
age groups II and III are scored on a ﬁve-point Likert scale
between 1 and 5 (ranging from never to always). Self-ratings
and proxy versions were administered to children of age groups
II and III and to their parents. The Haemo-QoL provides
values for the subscales and the total scale ranging from 0 to
100, with a high value indicating a high impairment in QoL.
Sample size
The sample size was calculated on the predicted bleeding
frequency. Based on literature reports[18], we assumed that the
bleeding frequency in children was 1.5 monthly bleeds per
patient treated episodically (and a standard deviation of 1.0
bleed) and 0.5 monthly bleeds in children treated prophylac-
tically, a difference judged as clinically relevant. Based on 80%
power to detect a signiﬁcant difference (P = 0.05, two-sided),
16 patients were required for each study group. To compensate
for potentially not evaluable patients (about one-third), we
planned to enrol at least 22 patients per group.
Statistics
As a pragmatic design was chosen [12], all data analysis was
carried out on an intention-to-treat basis, according to a pre-
established analysis plan. Descriptive statistics were used to
depict the study population. Proportions were compared by
using chi-squared tests with continuity correction, or Fishers
exact test when appropriate. Analysis of variance was used to
evaluate differences between the two study arms. Two-sided
signiﬁcance tests were used throughout. This report adheres to
the recommendations of the CONSORT group (Appendix 2)
[19] and its extension to pragmatic trials [20].
Results
Enrollment and follow-up
The enrollment period was December 1996 to December
1999. Seventy-two patients were assessed for eligibility in a
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consecutive and competitive fashion (Milan, 14; Rome, 10;
Bari, 9; Naples, 7; Bolzano, 5; Genoa, 5; Castelfranco V., 4;
Catania, 4; Florence, 4; Palermo, 4; Parma, 3; Vicenza, 3). Of
these, 17 were excluded because of unmet inclusion criteria
(nine parents refused randomization, three patients had
suffered from more than two bleeding episodes in the same
joints, three patients had not bled in the previous 6 months, one
child had radiologic signs of arthropathy, and one child
belonged to an unreliable (dysfunctional) family). As soon as
the plannednumber of patientswas achievedpatient enrollment
stopped. Forty-ﬁve patients were ultimately enrolled (Fig. 1):
23 were randomized to prophylaxis and 22 to episodic therapy.
Five of themwithdrew their consent immediately after knowing
their treatment assignment: two randomized to prophylaxis,
three to episodic therapy. They did not allow us to use any data
concerning their clinical status; therefore, they could not be
included in the intent-to-treat analysis. Forty patients effectively
received study treatments (Table 1). Four patients in each arm
chose to discontinue the follow-up during the study. Five
additional patients discontinued treatment for inhibitor devel-
opment (see below). Four patients in the prophylaxis arm and
ﬁve in the episodic therapy arm discontinued the assigned
treatment and switched to the other after 49–87 months (mean,
62 months): they continued to be regularly followed. All
analyses were carried out by intention-to-treat. The median
follow-up was 82.5 months, ranging from 2 to 163 months;
84.4 months (min–max, 2–96 months) in patients randomized
to prophylaxis and 81.9 months (min–max, 13–163 months) in
patients randomized to episodic therapy.
Outcomes
Children randomized to prophylaxis had a signiﬁcantly smaller
number of all bleeding episodes and joint bleeding episodes
compared with those randomized to the episodic therapy
(Table 2). Figure 2 shows the bleeding distribution in the two
treatment groups: 11 of 21 patients (52%) in the prophylaxis
group had on average<1 hemarthrosis per year, whereas only
4 of 19 patients in the episodic therapy group (21%) had the
same low frequency of bleeding (P < 0.05). Patients random-
ized to prophylaxis aged 3 years or less at study entry had a
much lower incidence of all bleeds (0.35 events per patient per
month) and joint bleeds (0.12 events per patient per month)
than patients older than 3 years at assignment (0.62 and 0.25
events per patient permonth). None of the patients who started
prophylaxis at the age of 3 years or earlier had on averagemore
than three bleeds per year, compared with 5 of 13 patients who
started prophylaxis later (38%). Bleeding was more frequent in
ankles, followed by elbows, knees, shoulders and hips (Fig. 3).
All bleeding episodes were treated with a median dose of
26.8 IU kg)1 (min–max, 14–100 IU kg)1), with no difference
between the two treatment groups.
Radiologic evaluation showed signs of hemophilic arthrop-
athy in six patients randomized to prophylaxis (29%) (median
Pettersson score 5; range, 3–14) and in 14 of those randomized
to episodic therapy (74%) (median Pettersson score 8; range, 2–
12) (P < 0.05). Prophylaxis was more effective when started at
younger ages. Indeed, none of the eight patients who started
prophylaxis at the age of 36 months or less had radiologic signs
of arthropathy, compared with 6 of the 13 older children on
prophylaxis (46%, P < 0.05). Of patients randomized to
episodic therapy, four of seven (57%) aged 36 months or less
and 10 of 12 (83%) of the older children had radiologic signs of
joint damage. The most frequently involved joints were elbows
and ankles, followed by knees. No alterations were found in
shoulders and hips.
A statistically signiﬁcant difference was found for bleeding
frequency between joints with and without subsequent radio-
logic signs of damage (P < 0.05); no correlation was found
between number of bleeds in each joint and Petterssons score.
Fig. 1. Flow diagram of participants through each stage of the study.
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Given the number of participants from each arm that changed
their treatment regimens during the period of study, bleeding
and radiologic data were reanalyzed according to actual
treatment (patients are censored at treatment switch or study
discontinuation, whichever came ﬁrst, Table 3).
Secondary analyses
None of the eight patients randomized to prophylaxis at the
age of 3 years or less had clinical signs of joint damage
compared to 3 of 10 patients of same age randomized to
episodic therapy; 2 of 13 patients from the prophylaxis group
older than 3 years showed some signs of joint involvement, and
2 of 9 of those on episodic therapy of the same age. No
correlation was found with bleeding frequency.
Less than 2% of the overall prescribed infusions were
missed. The recommended prophylactic dose of rFVIII
(25 IU kg)1 body weight) was sufﬁcient to maintain FVIII
levels above 1% in 7 of 18 patients on prophylaxis (35%)
without inhibitors. Two patients had to increase the three-
times-weekly dose to 30–40 IU kg)1 independently from the
trough level, owing to a high frequency of bleeding. Five had to
increase the dose of the infusion with a longer interval before
the following infusion to 30–40 IU kg)1 in order to maintain
Table 1 Baseline demographic characteristics of trial groups
Characteristic
Prophylaxis
(n = 21)
Episodic
treatment (n = 19) P value
Age, months
Mean ± SD 49.7 ± 26.9 48.8 ± 21.2 ns
Median (min–max) 50 (10–84) 48 (14–84)
Age groups, n (%)
£36 months 8 (38) 7 (38) ns
37–60 months 6 (29) 6 (32)
>60 months 7 (33) 6 (32)
Age at diagnosis, months
Mean ± SD 5.7 ± 6.2 8.8 ± 10.1 ns
Median (min–max) 6 (0–23) 6 (0–32)
Body mass index, kg m)2
Mean ± SD 16.4 ± 0.8 16.4 ± 0.7 ns
Median (min–max) 16.2 (15.5–18.2) 15.5 (15.5–17.9)
SD, standard deviation.
ns, not signiﬁcant.
Table 2 Outcome data. Patients are divided on the basis of randomization
Variable
Prophylaxis
(n = 21)
Episodic
treatment
(n = 19) P value
No. of months in study
Mean 72.5 76.0 ns
Median (min–max) 81.9 (2–96) 84.4 (13–163)
No. of patient years 127 120
Age at the end of the study (months)
Mean 122.2 124.8 ns
Median (min–max) 148 (18–193) 154 (27–204)
Total bleeding events per patient
Mean 37.9 82.4 <0.01
Median (min–max) 25 (0–233) 76 (0–305)
Mean no. of events
per patient
per month
0.52 1.08
Median no. of events per
patient per year
4.0 12.0
No. of hemarthroses per patient
Mean 14.7 40 <0.01
Median (min–max) 7 (0–68) 36 (0–117)
Mean no. of events per
patient per month
0.20 0.53
Median no. of events per
patient per year
1.0 5.5
Radiographic ﬁndings
Patients with joint
damage, no. (%)
6 (29%) 14 (74%) <0.05
Patients without joint
damage, no.
15 5
Overall FVIII concentrate usage per infusion (IU kg)1 per infusion)
Mean 31.7 31.7 ns
Median (min–max) 26.9 (14–157) 26.3 (7–208)
Total no. of FVIII units infused
Prophylaxis 12 239,873 3 961 478 <0.01
Joint bleeding 304 732 701 775 <0.01
Total 13 477 251 5 749 085 <0.01
ns, not signiﬁcant.
Fig. 2. Patient distribution according to the observed average number of
joint bleeds per year and treatment arm. Grey columns represent patients
on episodic treatment. White columns represent patients on prophylaxis.
Fig. 3. Total number of joint bleeding events according to the sites of
occurrence and treatment arm.
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FVIII levels above 1%; the remaining four patients continued
with the same dose despite trough FVIII levels below 1%. No
correlation was found between bleeding frequency and trough
FVIII levels.
Monthly factor usage per patient month was 8852 IU in
patients on prophylaxis vs. 3981 IU in patients on episodic
therapy. With an average price per IU of recombinant FVIII
concentrates of 0.75€, the yearly cost of prophylaxis was
79 668€ compared with 35 829€ on episodic therapy. The
incremental cost-efﬁcacy ratio per bleeding event avoided in
patients on prophylaxis was 7537€ (10 049.6 IU · 0.75€). The
incremental cost-efﬁcacy ratio formaintaining all joints pristine
over the whole treatment period was 201 601.12€
(268 801.5 IU · 0.75€).
QoL as evaluated by children and adolescents was on
average good, with a total Haemo-QoL score of 29.97
(SD = 9.3) for both age groups together, with similar ratings
given by parents (mean 28.70, SD = 11.2). Children and
adolescents, as well as their parents, reported mainly impair-
ments in the dimension friends (mean 56.3, SD = 22.2),
perceived support (mean 52.92, SD = 30.2) and dealing
(mean 51.15, SD = 33.1).
A signiﬁcant difference was found between children and
adolescents on episodic treatment vs. prophylaxis for the
dimension family (Students t-test, P < 0.029), which was
more impaired in the episodic treatment (mean 44.0, SD 22.6)
than in the prophylaxis group (mean 11.27, SD 8.7) (Fig. 4).
No difference was revealed between the treatment groups in the
parents ratings. Moreover, children on episodic treatment felt
often or always more overprotected both by their mother
(80% vs. 11%) and father (80% vs. 20%) than children on
prophylaxis (Fig. 5). Twenty per cent of children and adoles-
cents on episodic treatment perceived that their parents had
often or always to limit their time at work or leisure because
of their hemophilia compared with none in the prophylaxis
group, where only 10% of children perceived that their parents
had only sometimes their work or leisure time limited.
Adverse events
Ten of 20 patients on prophylaxis required indwelling catheters
(Port-a-Cath), whereas none of the patients in the episodic
therapy group did. Six patients with indwelling catheters had
an infection within 1–60 months from insertion (median
6 months). In two of these patients the catheter was removed
and this required hospitalization for 2 days.
Five patients developed inhibitors (12.5%): three patients
were in the prophylaxis group (14.3%), aged 10, 35 and
63 months at enrollment, and they developed inhibitors after
2–4 months of follow-up, after 24–48 exposure days. The
remaining two patients with inhibitors were in the episodic
therapy group (10.5%), aged 19 and 49 months, and they
developed inhibitors after 13 and 24 months, at 20 and 24
exposure days. Patients with inhibitors in the prophylaxis
group had indwelling catheters and one of them had developed
an infection 2 weeks before inhibitor occurrence, whereas none
of the patients with inhibitors in the episodic group had central
venous access or had undergone surgery or intensive treatment.
No patient suffered from life- or limb-threatening bleeding
events or from bleeding events that required hospitalization.
Discussion
This randomized controlled trial was designed to evaluate the
impact of two treatment options in a population of young
Table 3 Bleeding events and radiographic data by actual treatment
(patients are censored at treatment switch or study discontinuation,
whichever came ﬁrst)
Variable
Prophylaxis
(n = 21)
Episodic
Treatment
(n = 19) P value
No. of months in randomization arm
Mean 46.2 51.8 ns
Median (min–max) 54.5 58.6
No. of patient years 81 82
Total bleeding events per patient
Mean 5.0 24.9 <0.01
Median (min–max) 1 7.5
No. of events per patient
per month
0.11 0.48
No. of hemarthroses per patient
Mean 2.48 12.42 <0.01
Median (min–max) 0 4
No. of events per patient
per month
0.05 0.24
Radiographic ﬁndings
Joint damage, no. (%) 0 5 ns
No joint damage, no. (%) 21 14
ns, not signiﬁcant.
Fig. 4. Comparison between childrens and adolescents QoL (age groups
II and III) by means of the Haemo-QoL across treatment regimes: pro-
phylaxis (grey bars) and episodic treatment (black bars).
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children with severe hemophilia. The design of the study, the
study population (with a relatively broad range of ages), the
modalities of treatment (episodic therapy vs. prophylactic
infusions three times weekly), the primary and secondary
outcomes, and the type of analysis by intention-to-treat were all
chosen with the goal of evaluating the beneﬁt of prophylaxis
from a pragmatic point of view [12]. The aim was not only to
gather more evidence on the superiority of prophylaxis, which
at the time of this study stemmed only from the evaluation of
retrospective cohorts, but also to provide more information
that might help all the stakeholders in hemophilia care (namely
patients, physicians and budget holders) to make evidence-
based decisions.
Prophylaxis at the average dose of 30 IU kg)1 three times a
week was able to signiﬁcantly reduce the overall bleeding
frequency, and in particular that due to hemarthroses. The
mean incidence of joint bleeding was relatively high
(0.20 events per patient per month) if compared with that of
other cohorts of patients [9,21]. In particular, the Joint
Outcome Study (JOS) [9], found a 4-fold lower incidence
(0.05 events per patient per month) in patients on prophylaxis.
This difference is perhaps explained by the different ages at
enrollment of the two study populations: ours included patients
up to 7 years of age, while the JOS only included patients aged
up to 2.5 years. In the subgroup of patients with a younger age
(equal to or lower than 3 years) the incidence was only
0.12 events per patient per month (i.e. much closer to that
observed in the JOS). In addition, one should take into account
the longer follow-up of our study as well as the intention-to-
treat analysis that did not exclude patients who switched
treatment during the study.
Our study shows that prophylaxis was able to reduce the risk
of joint damage. The image-proven evidence of arthropathy
was observed in three-quarters of the patients randomized to
episodic therapy, compared with only one-quarter of those
randomized to prophylaxis. Patients who started prophylaxis
at the age of 3 years or less showed more pristine joints.
Nevertheless, those children who initiated prophylactic treat-
ment after the third year of age also beneﬁted from prophy-
laxis. Compared with the JOS ﬁndings, our study found a
higher percentage of patients with radiologic evidence of joint
damage, due to the older population recruited and perhaps also
to the much longer follow-up. Prophylaxis was able to reduce
the risk of joint damage also in those patients who started
prophylaxis at later ages, although with lower efﬁcacy. This is
the ﬁrst prospective and controlled trial that provides direct
evidence that early prophylaxis (i.e. prophylaxis started in the
ﬁrst years of life) is more effective than delayed prophylaxis, in
agreement with previous retrospective studies [3,6,22]. These
ﬁndings are partially in contrast to the recently published
German retrospective study by Schobess et al. [23], who
compared primary versus secondary prophylaxis started early.
These authors found no statistical difference in imaging-proven
hemophilic joint damage between the two populations, but
those populations had quite wide age ranges (0.1–6.7 and 0.8–
16 years, respectively), which are likely to have inﬂuenced the
results because of poorly homogeneous populations.
In addition, the present study provides further evidence on
the high rate of infectious complications of indwelling cathe-
ters, which according to some data [24] may represent one of
the risk factors of inhibitor development: 60% of our patients
with Port-a-Caths had catheter and systemic infections, and
one of these patients developed an inhibitor a few days after
infection occurrence. According to our experience, venous
access probably represents the major barrier to prophylaxis,
and central venous devices are not a reliable solution, the
patients being exposed to a high rate of complications [25]. This
issue has prompted either the use of arterio-venous ﬁstulas [26],
or the implementation of prophylaxis that adopts an escalating
frequency of infusion [21].
As expected, the cost of prophylaxis is more than double that
of episodic therapy. Similar ﬁgures have been found by others
[9,15,27], with differences between the two costs of treatment
options ranging from 2.4-fold [9] to 3.1-fold [27]. The
Fig. 5. Frequency of answers often/always to items in the dimension family of the self-report of children and adolescents of the Haemo-QoL across
treatment regimes. Grey columns represent patients on episodic treatment. White columns represent patients on prophylaxis.
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incremental cost-effectiveness ratio per bleed avoided showed
the need for a high investment of resources (7537€), much
higher than that reported by the only other study that carried
out a cost-effectiveness analysis of prophylaxis in children
based on empiric data [27]. The huge difference is probably due
to the design of that study (retrospective, non-randomized) and
the shorter length of the time period of data collection
(2 years). Furthermore, we calculated how much expenditure
on average is required to maintain pristine joints in a child with
hemophilia: about 200 000€ over a period of approximately
7 years (about 2500€ monthly).
QoL was found to be signiﬁcantly worse in children on
episodic treatment in the dimension family. Indeed, children
on episodic treatment complained about the overprotection of
their parents and reported that their parents had to limit their
time at work or leisure. It would seem that prophylaxis gives
parents deﬁnite reassurance, so that they do not have the need
to look after their children in the same obsessivemanner seen in
parents of children treated episodically, who are afraid that
their children could hurt themselves and bleed. These ﬁndings
are similar to those from the EuropeanHaemo-QoL study [28],
where in general prophylaxis seemed to be associated with less
impairment in QoL. It can be argued that prophylaxis should
be expected to have a greater positive impact on childrens
QoL. Small children might not be able to grasp the beneﬁts of
this burdensome treatment and are more troubled by the pain
and the time spent having the injections.
Strengths of this study are the randomized controlled
design, the intention-to treat analysis, the pragmatic
approach, with a relatively broad range of patients with
different ages at study entry and with modalities of treatment
that reﬂect the common practise, an approach that provides
information that can be extrapolated to all children with
hemophilia, and the longest follow-up so far. Limits are
represented by the relatively small number of hemophilia
patients selected from a relatively low number of children,
even though the competitive and consecutive enrollment
should have limited selection biases. Other limits are the use
of plain-ﬁlm radiography and of the WFH Orthopedic Joint
Score, because these two methods are relatively insensitive to
early orthopedic alterations in children. We have not
considered the cost of catheter infections in the 10 patients
on prophylactic treatment. However, this cost can be
considered negligible, when compared with the overall cost
of clotting factors: even assuming that all infections lead to a
catheter replacement, this would increase the total prophy-
laxis cost by about 0.02% to 0.2%, given the current cost of
catheter implantation [29]. Another limitation is that QoL
was tested only at the end of the study, because the Haemo-
QoL was not available at the time of patient enrollment and
only some of the patients were willing to complete the
questionnaire.
In conclusion, this study conﬁrms bymeans of a randomized
design the efﬁcacy of prophylaxis in preventing bleeding and
image-proven arthropathy in children with severe hemophilia.
Moreover, it conﬁrms that early prophylaxis is more efﬁcacious
than delayed prophylaxis, even though the latter still generates
substantial beneﬁts to these patients. The higher costs of
prophylaxis compared with episodic therapy are balanced by a
better orthopedic outcome and hence a better quality of life.
Addendum
A. Gringeri and P. M. Mannucci designed the research,
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quality of life analyses. All authors reviewed the paper.
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CONSORT Statement 2001 Checklist [19]
Paper section and topic Item Descriptor Reported on page #
Title & Abstract 1 How participants were allocated to interventions
(e.g. random allocation, randomized or randomly
assigned).
1–2
Introduction
Background
2 Scientiﬁc background and explanation of rationale. 4
Methods
Participants
3 Eligibility criteria for participants and the settings and
locations where the data were collected.
6
Objectives 5 Speciﬁc objectives and hypotheses. 6
Interventions 4 Precise details of the interventions intended for each
group and how and when they were actually
administered.
7
Outcomes 6 Clearly deﬁned primary and secondary outcome
measures and, when applicable, any methods used to
enhance the quality of measurements (e.g. multiple
observations, training of assessors).
8
Sample size 7 How sample size was determined and, when applicable,
explanation of any interim analyses and stopping rules.
10
Randomization – sequence generation 8 Method used to generate the random allocation
sequence, including details of any restrictions (e.g.
blocking, stratiﬁcation)
7
Randomization – allocation concealment 9 Method used to implement the random allocation
sequence (e.g. numbered containers or central
telephone), clarifying whether the sequence was
concealed until interventions were assigned.
7
Randomization
– implementation
10 Who generated the allocation sequence, who enrolled
participants, and who assigned
participants to their groups.
7
Blinding (masking) 11 Whether or not participants, those administering the
interventions, and those assessing
the outcomes were blinded to group assignment. If
done, how the success of blinding
was evaluated.
6
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Paper section and topic Item Descriptor Reported on page #
Statistical methods 12 Statistical methods used to compare groups for primary
outcome(s); methods for
additional analyses, such as subgroup analyses and
adjusted analyses.
10
Results
Participant ﬂow
13 Flow of participants through each stage (a diagram is
strongly recommended). Speciﬁ
cally, for each group report the numbers of participants
randomly assigned, receiving
intended treatment, completing the study protocol, and
analyzed for the primary
outcome. Describe protocol deviations from study as
planned, together with reasons.
11
Recruitment 14 Dates deﬁning the periods of recruitment and follow-up. 11
Baseline data 15 Baseline demographic and clinical characteristics of each
group.
11
Numbers analyzed 16 Number of participants (denominator) in each group
included in each analysis and
whether the analysis was by intention-to-treat. State
the results in absolute numbers
when feasible (e.g. 10/20, not 50%).
11
Outcomes and estimation 17 For each primary and secondary outcome, a summary of
results for each group, and the
estimated eﬀect size and its precision (e.g. 95% conﬁ-
dence interval).
11
Ancillary analyses 18 Address multiplicity by reporting any other analyses
performed, including subgroup
analyses and adjusted analyses, indicating those pre-
speciﬁed and those exploratory.
13
Adverse events 19 All important adverse events or side-eﬀects in each
intervention group.
14
Discussion
Interpretation
20 Interpretation of the results, taking into account study
hypotheses, sources of potential
bias or imprecision and the dangers associated with
multiplicity of analyses and out
comes.
15
Generalizability 21 Generalizability (external validity) of the trial ﬁndings. 17
Overall evidence 22 General interpretation of the results in the context of
current evidence.
17
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